KFF Health News’ ‘What the Health?’: Ousted CDC Officials Clap Back at RFK Jr.
The Host Julie Rovner KFF Health News @jrovner @julierovner.bsky.social Read Julie’s stories. Julie Rovner is…
KFF Health News’ ‘What the Health?’: Ousted CDC Officials Clap Back at RFK Jr.
The Host Julie Rovner KFF Health News @jrovner @julierovner.bsky.social Read Julie’s stories. Julie Rovner is chief Washington correspondent and host of KFF Health News’ weekly health policy news podcast, “What the Health?” A noted expert on health policy issues, Julie is the author of the critically praised reference book “Health Care Politics and Policy A…
KFF Health News’ ‘What the Health?’: Ousted CDC Officials Clap Back at RFK Jr.
The Host Julie Rovner KFF Health News @jrovner @julierovner.bsky.social Read Julie’s stories. Julie Rovner is chief Washington correspondent and host of KFF Health News’ weekly health policy news podcast, “What the Health?” A noted expert on health policy issues, Julie is the author of the critically praised reference book “Health Care Politics and Policy A…
KFF Health News’ ‘What the Health?’: Ousted CDC Officials Clap Back at RFK Jr.
The Host Julie Rovner KFF Health News @jrovner @julierovner.bsky.social Read Julie’s stories. Julie Rovner is chief Washington correspondent and host of KFF Health News’ weekly health policy news podcast, “What the Health?” A noted expert on health policy issues, Julie is the author of the critically praised reference book “Health Care Politics and Policy A…
KFF Health News’ ‘What the Health?’: Ousted CDC Officials Clap Back at RFK Jr.
The Host Julie Rovner KFF Health News @jrovner @julierovner.bsky.social Read Julie’s stories. Julie Rovner is chief Washington correspondent and host of KFF Health News’ weekly health policy news podcast, “What the Health?” A noted expert on health policy issues, Julie is the author of the critically praised reference book “Health Care Politics and Policy A…
KFF Health News’ ‘What the Health?’: Ousted CDC Officials Clap Back at RFK Jr.
The Host Julie Rovner KFF Health News @jrovner @julierovner.bsky.social Read Julie’s stories. Julie Rovner is chief Washington correspondent and host of KFF Health News’ weekly health policy news podcast, “What the Health?” A noted expert on health policy issues, Julie is the author of the critically praised reference book “Health Care Politics and Policy A…
Roche’s Metabolic Drug Strategy Extends to the Liver Disease MASH With $2.4B 89bio Acquisition
Roche is buying 89bio to get pegozafermin, a drug currently in two Phase 3 studies for the fatty liver disease MASH. Beyond the $2.4 billion payable when the deal closes, another $1.1 billion in contingent value right payments is tied to the achievement of commercial milestones for the projected blockbuster seller. The post Roche’s Metabolic…
Roche’s Metabolic Drug Strategy Extends to the Liver Disease MASH With $2.4B 89bio Acquisition
Roche is buying 89bio to get pegozafermin, a drug currently in two Phase 3 studies for the fatty liver disease MASH. Beyond the $2.4 billion payable when the deal closes, another $1.1 billion in contingent value right payments is tied to the achievement of commercial milestones for the projected blockbuster seller. The post Roche’s Metabolic…
Roche’s Metabolic Drug Strategy Extends to the Liver Disease MASH With $2.4B 89bio Acquisition
Roche is buying 89bio to get pegozafermin, a drug currently in two Phase 3 studies for the fatty liver disease MASH. Beyond the $2.4 billion payable when the deal closes, another $1.1 billion in contingent value right payments is tied to the achievement of commercial milestones for the projected blockbuster seller. The post Roche’s Metabolic…
Roche’s Metabolic Drug Strategy Extends to the Liver Disease MASH With $2.4B 89bio Acquisition
Roche is buying 89bio to get pegozafermin, a drug currently in two Phase 3 studies for the fatty liver disease MASH. Beyond the $2.4 billion payable when the deal closes, another $1.1 billion in contingent value right payments is tied to the achievement of commercial milestones for the projected blockbuster seller. The post Roche’s Metabolic…
Roche’s Metabolic Drug Strategy Extends to the Liver Disease MASH With $2.4B 89bio Acquisition
Roche is buying 89bio to get pegozafermin, a drug currently in two Phase 3 studies for the fatty liver disease MASH. Beyond the $2.4 billion payable when the deal closes, another $1.1 billion in contingent value right payments is tied to the achievement of commercial milestones for the projected blockbuster seller. The post Roche’s Metabolic…
